FORMATION DISCLOSURE CITATION

Δth	Docket	No

Serial No.

39-288 Applicant 10/654,994

I sheets if necessary)

FERGUSON, Mark W.J. Filing Date

TC/A.U.

September 5, 2003

1647

EXAMINER			U.S. PATENT DOCUMENTS			FILING	DATE
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPR	OPRIA:
		ļ					
		<u> </u>					
		1					
		<u> </u>					
							
		 					
		L	I		L	l	
		FOI	REIGN PATENT DOCUMENTS				
						TRANS	LATIO
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NC
		1					
							_
		1					
-			ľ		!		
				- t			-
	OTHER DOC	IMENTS (notedian Author Title Date Porting				1
			ncluding Author, Title, Date, Pertine			(TCF 02	
	Occleston et al, "Prever	ntion and red	uction of scarring in the skin by Transform	ing Growth I	Factor beta 3		
	Occleston et al, "Prever laboratory discovery to	ntion and red		ing Growth I	Factor beta 3		
	Occleston et al, "Prever laboratory discovery to Proof Copy	ntion and red clinical phar	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed	ning Growth I n. 19(8):1047	Factor beta 3 7-63 (2008) -	Uncorre	cted
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat	ntion and red clinical phar ionof TGF-β	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed	ning Growth I n. 19(8):1047	Factor beta 3 7-63 (2008) -	Uncorre	cted
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co	ntion and red clinical phar ionof TGF-B ell Science 10	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed and TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995)	ning Growth 1 n. 19(8):1047 F-β ₃ to cutan	Factor beta 3 7-63 (2008) – eous rat wou	Uncorre	cted
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase II Clinic	ntion and red clinical phar ionof TGF-B ell Science 10 al Trial RN10	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed, and TGF-β, or exogenous addition of TG 08:985-1002 (1995) 001-1011. RNS announcement, released to	ning Growth 1 n. 19(8):1047 F- $β_3$ to cutan o the London	Factor beta 3 7-63 (2008) – eous rat wou	Uncorre	cted
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase II Clinic September 2006, Reno	ntion and red clinical phar ionof TGF-β ell Science 10 al Trial RN10 vo Announce	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed and TGF-β ₂ or exogenous addition of TG 88:985-1002 (1995) 001-1011. RNS announcement, released to 8 Highly Positive Phase II Trial Results for	ing Growth I n. 19(8):1047 F-β ₃ to cutan o the London r Juvista	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha	Uncorre	ces
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase Il Clinic September 2006, Renov Renovo Phase Il Clinic	ntion and red clinical phar ionof TGF-β ell Science 10 al Trial RN10 vo Announce al Trial RN10	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed, and TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995) 001-1011. RNS announcement, released to ship Positive Phase II Trial Results for 10:10-0050, RNS announcement, released to 10:10-0050, RNS announcement, released to	ing Growth I n. 19(8):1047 F-β ₃ to cutan o the London r Juvista	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha	nds reduinge 28	ces
	Occleston et al, "Prever laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase Il Clinic September 2006, Renov Renovo Phase Il Clinic	ntion and red clinical phar ionof TGF-β. ell Science 10 al Trial RN10 vo Announce al Trial RN10 LC, "Statistic	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed., and TGF- β_2 or exogenous addition of TG 18:985-1002 (1995) 101-1011. RNS announcement, released to s Highly Positive Phase II Trial Results for 101-0030, RNS announcement, released to ally significant Efficacy of Juvista Demon	ing Growth I n. 19(8):1047 F-β ₃ to cutan o the London r Juvista	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha	nds reduinge 28	ces
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Cc Renovo Phase II Clinic September 2006, Renov Renovo Phase II Clinic 2007, Renovo Group P. Substance Manufacture	ntion and red clinical phar ionof TGF-β ell Science 10 al Trial RN10 vo Announce al Trial RN10 LC, "Statistic d by Lonza E	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed., and TGF- β_2 or exogenous addition of TG 18:985-1002 (1995) 101-1011. RNS announcement, released to s Highly Positive Phase II Trial Results for 101-0030, RNS announcement, released to ally significant Efficacy of Juvista Demon	ning Growth In. 19(8):1047 F-β ₃ to cutan of the London r Juvista the London estrated in Phenomena.	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U	nds reduced inge 28 inge 12 Sesing Drug	ces
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase Il Clinic September 2006, Renov Renovo Phase Il Clinic 2007, Renovo Group P Substance Manufacture Cox, David A, "Transf	ntion and red clinical phar ionof TGF-β. Ell Science 10 al Trial RNI0 al Trial RNI0 LC, "Statistic d by Lonza E orming Grow	uction of scarring in the skin by Transform maceutical*, J. Biomater. Sci. Polymer Ed and TGF-β ₂ or exogenous addition of TG 8:985-1002 (1995) 201-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 201-0050, RNS announcement, released to ally significant Efficacy of Juvista Demonstologies.	ning Growth I n. 19(8):1047 F-β ₃ to cutan the London r Juvista the London strated in Pho-	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U 7-371 (1995)	nds reduced in the second seco	ected ces eptem
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of Co Renovo Phase Il Clinic September 2006, Renov Renovo Phase Il Clinic 2007, Renovo Group P Substance Manufacture Cox, David A, "Transf	ntion and red clinical phar ionof TGF-β, ell Science IG al Trial RNI wo Announce al Trial RNI LC, "Statistic di by Lonza E orming Grow beta]3 in the	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed. and TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995) 201-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 10:10050, RNS announcement, released to ally significant Efficacy of Juvista Demon iologics".	ning Growth I n. 19(8):1047 F-β ₃ to cutan the London r Juvista the London strated in Pho-	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U 7-371 (1995)	nds reduced in the second seco	ected ces eptem
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of CC Renovo Phase II Clinic September 2006, Renovo Phase II Clinic 2007, Renovo Group P. Substance Manufacture Cox, David A., "Transf Hirshberg et al, "Ticare 14(2):91-95 (2001)	ntion and red clinical phar ionof TGF-β ell Science 10 al Trial RN10 vo Announce al Trial RN10 LC, "Statistic d by Lonza E orming Grow beta]3 in the	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed. and TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995) 201-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 10:10050, RNS announcement, released to ally significant Efficacy of Juvista Demon iologics".	ing Growth In. 19(8):1045 F-β ₃ to cutan the London Juvista the London strated in Phonal 19(5):35 ary Report", A	Factor beta 3 7-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U 7-371 (1995) Advances in 1	nds reducinge 28 nge 12 Sesing Drug Skin & V	ces eptem g
	Occlession et al., "Preve laboratory discovery io Aboratory discovery io Proof Copy Shah et al, "Neutralisat scarring", Journal of Ct Renovo Phase Il Clinic petember 2006, Renovo Renovo Group P Substance Manufacture Cox, David A., "Transl Hirshberg et al, "TGF-Care 14(2)91-95 (2001 LeGrand, Edmund K.," 20)4348-548 (1998)	ntion and red clinical phar ionof TGF-β lell Science 10 al Trial RNIu vo Announce al Trial RNIu tc, "Statistic d by Lonza Forming Grow beta]3 in the) 'Preclinical F	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed. and TGF-B ₂ or exogenous addition of TG 88:985-1002 (1995). 201-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 201-0050, RNS announcement, released to salight significant Efficacy of Juvista Demonitologics". 201-202 (2018). 2018 Teacher Street Stree	hing Growth In. 19(8):1047 F- β_3 to cutan to the London r Juvista the London histrated in Phonal 19(5):35 ary Report", A Journal Healin	Factor beta 3 7-63 (2008) – eous rat wou Stock Excharase 2 Trial U 7-371 (1995) Advances in 3 g", Am. J. St	nge 28 nge 12 Sising Drug Skin & V	ces eptem g
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutraliss scarring," Journal of Cc. Renovo Phase II Clinic September 2006, Renovo Phase II Clinic 2007, Renovo Group P. Substance Manufacture Cox, David A., "Transf Hirshberg et al, "TGF-1 Care 14(2)-19-5 (2001 LeGrand, Edmund K., 2A):485-54S (1998)	ntion and red clinical phar ionof TGF-Bell Science 10 al Trial RNII LC, "Statistic d by Lonza Forming Grow beta]3 in the) Preclinical Fy and Safety of and Safety of a safety of a safety of a safety of a clinical pharmace.	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed Jand TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995) 001-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 1001-0050, RNS announcement, released to tally significant Efficacy of Juvista Demon Biologies" and the state of	hing Growth In. 19(8):1047 F- β_3 to cutan or Juvista the London strated in Phonal 19(5):35 ary Report", Jound Healin ant Human P	Factor beta 3 r-63 (2008) – eous rat wou Stock Excha ase 2 Trial U 7-371 (1995) Advances in g", Am. J. St latelet-Deriv	nge 28 nge 12 Sesing Drug Skin & V	ected ces eptem g
	Occlession et al., "Preve laboratory discovery to Proof Copy Shah et al., "Neutralisat scarring", Journal of Cc. Renovo Phase II Clinic September 2006, Renovo Group P. Renovo Group P. Substance Manufacture Cox, David A., "Transl Hirshberg et al., "TGF-1 Care 14(2):91-95 (2001) LeGrand, Edmund K., 2A):485-545 (1998) Weiman et al., "Efficac." Factor-BB (Becaplemir Factor-BB (Becaplemir Factor-BB (Becaplemir Factor-BB) (Becaplemir Fact	ntion and red clinical phar clinical phar ionof TGF-Bell Science 10 all Trial RNI4 to Announce al Trial RNI4 tc, "Statistic d by Lonza E forming Grow beta] 3 in the preclinical Freching and Safety of and Safety of pharming in Patients	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed, and TGF-B ₂ or exogenous addition of TG 8:985-1002 (1995) 301-1011. RNS announcement, released to 8 Highly Positive Phase II Trial Results for 301-0030, RNS announcement, released to allogics" and the state of the st	ning Growth In. 19(8):1047 F- β_3 to cutan the London of the London strated in Phonal 19(5):35 ary Report", a count Healin ant Human P	Factor beta 3 r-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U 7-371 (1995) Advances in a g", Am. J. Si clatelet-Deriv Care 21(5):82	nge 28 nge 12 Sessing Drug Skin & V arg. 176() ed Grow	ected ces eptem g Vounc Suppl
	Occleston et al, "Prevei laboratory discovery to Proof Copy Shah et al, "Neutralisat scarring", Journal of CC Renovo Phase II Clinic September 2006, Renovo Phase II Clinic 2007, Renovo Group P Substance Manufacture Cox, David A, "Transt Hirshberg et al, "Ticare 14(2)-91-95 (2001 LeGrand, Edmund K., Care 14(2)-91-95 (2001 LeGrand, Edmund K., 2A)-485-545 (1998) Weiman et al, "Efficacy Factor-BB (Becaplenin Nanney, Lillian B, "EF	ntion and red clinical phar ionof TGF-Bill Science I (a I Trial RNII) vo Announce al Trial RNII vo Announce al Trial RNII (c., "Statistic di by Lonza E orming Grov beta]3 in the) Preclinical Fy and Safety (y) in Patients.	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed Jand TGF-B ₂ or exogenous addition of TG 18:985-1002 (1995) 001-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 1001-0050, RNS announcement, released to tally significant Efficacy of Juvista Demon Biologies" and the state of	ning Growth In. 19(8):1047 F- β_3 to cutan the London of the London strated in Phonal 19(5):35 ary Report", a count Healin ant Human P	Factor beta 3 r-63 (2008) – eous rat wou Stock Excha Stock Excha ase 2 Trial U 7-371 (1995) Advances in a g", Am. J. Si clatelet-Deriv Care 21(5):82	nge 28 nge 12 Sessing Drug Skin & V arg. 176() ed Grow	ected ces eptem g Vounc Suppl
	Occlession et al., "Preve haboratory discovery to Proof Copy Shah et al., "Neutralisat scarring", Journal of Cc. Renovo Phase II Clinic September 2006, Renovo Phase II Clinic 2007, Renovo Group Copo, Renovo Phase II Clinic 2007, Renovo Group Copo, Renovo Preventa (2019), 195 (2001) LeGrand, Edmand K., 2A).485-54S (1998) Weiman et al., "Effection Education Copo, Lillian B., "Egebermatol. 94, 624-629) Permatol. 94, 624-629 (1909).	ntion and red clinical phar ionof TGF-B-III Science I(al Trial RNII(vo Announce al Trial RNII(c, "Statistic d by Lonza E orming Grow beta] in the hold of the control of th	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed, and TGF-B ₂ or exogenous addition of TG 8:985-1002 (1995) 301-1011. RNS announcement, released to shighly Positive Phase II Trial Results for 3010-10050, RNS announcement, released to ally significant Efficacy of Juvista Demon iologics" at 125 (1997) with Factor-Beta 3.", Cell Biology Internation Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplermin (rhPDGF-BB) in Word To Treatment of Pressure Ulcers: A Preliminary tremiseof Becaplerminary tremise	ining Growth in. 19(8):1047. F-β ₂ to cutan the London r Juvista the London strated in Pho onal 19(5):35 ary Report", //ound Healin ant Human P "", Diabetes G or During WG	Factor beta 3 7-63 (2008) — eous rat wou Stock Excha ase 2 Trial U 7-371 (1995) Advances in g", Am. J. St latelet-Deriv Care 21(5):82 und Repair"	nge 28 nge 12 Sesing Drug Skin & V arg. 176(: ed Grow: 22-827 (1, J. Inves	ected ces eptem g Vound Suppl th 998)
	Occlession et al., "Preve haboratory discovery to Proof Copy Shah et al., "Neutralisat scarring", Journal of Cc. Renovo Phase II Clinic September 2006, Renovo Phase II Clinic 2007, Renovo Group Copo, Renovo Phase II Clinic 2007, Renovo Group Copo, Renovo Preventa (2019), 195 (2001) LeGrand, Edmand K., 2A).485-54S (1998) Weiman et al., "Effection Education Copo, Lillian B., "Egebermatol. 94, 624-629) Permatol. 94, 624-629 (1909).	ntion and red clinical phar ionof TGF-B-III Science I(al Trial RNII(vo Announce al Trial RNII(c, "Statistic d by Lonza E orming Grow beta] in the hold of the control of th	uction of scarring in the skin by Transform maceutical", J. Biomater. Sci. Polymer Ed, and TGF-B ₂ or exogenous addition of TG 8:985-1002 (1995) 301-1011. RNS announcement, released to 8 Highly Positive Phase II Trial Results for 301-0030, RNS announcement, released to allogics" and the state of the st	ining Growth in. 19(8):1047. F-β ₂ to cutan the London r Juvista the London strated in Pho onal 19(5):35 ary Report", //ound Healin ant Human P "", Diabetes G or During WG	Factor beta 3 7-63 (2008) — eous rat wou Stock Excha ase 2 Trial U 7-371 (1995) Advances in g", Am. J. St latelet-Deriv Care 21(5):82 und Repair"	nge 28 nge 12 Sesing Drug Skin & V arg. 176(: ed Grow: 22-827 (1, J. Inves	ccted ces supplemental control

/David Romeo/ (12/15/2009)

*Examiner